Manufacturing Scale INmune Bio is actively pursuing commercial-scale manufacturing through partnerships with CGT Catapult and Cellectis, signaling a clear sales opportunity for CDMOs and manufacturing service providers to support INKmune and other cell therapy platforms from development through scale.

NK Collaboration INmune Bio's lead asset INKmune primes NK cells to target residual disease, creating opportunities for pharma partners seeking NK-based immunotherapies or residual-disease strategies to pursue co-development, licensing, or collaboration around NK cell platforms.

Combination Potential New preclinical data on INB03 (XPro1595) showing resistance reversal and metastasis reduction in HER2+ models can open doors for collaboration with oncology drug developers exploring combination regimens with INB03 or related pathways.

Rare Disease Partnerships INmune Bio expanding its Anthony Nolan partnership to advance CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB) underscores a path to partnerships within rare diseases and stem cell therapy networks, offering potential for joint development, manufacturing support, and access to patient advocacy channels.

Investment Readiness With a modest revenue base and around $19 million in funding, INmune Bio presents opportunities for partnerships with investors, grant programs, and strategic co-development deals to accelerate clinical programs and scale operations.